Shattuck Labs (NASDAQ:STTK) Insider Abhinav Shukla Sells 2,032 Shares of Stock

Shattuck Labs, Inc. (NASDAQ:STTK) insider Abhinav Shukla sold 2,032 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $7.01, for a total value of $14,244.32. Following the sale, the insider owned 81,258 shares of the company’s stock, valued at $569,618.58. This represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK opened at $6.67 on Friday. The stock has a 50-day simple moving average of $6.61 and a 200-day simple moving average of $4.46. The stock has a market capitalization of $511.46 million, a P/E ratio of -10.59 and a beta of 1.18. Shattuck Labs, Inc. has a 1 year low of $0.71 and a 1 year high of $8.33.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same quarter in the previous year, the business posted ($0.27) earnings per share. Analysts predict that Shattuck Labs, Inc. will post -0.51 earnings per share for the current year.

Hedge Funds Weigh In On Shattuck Labs

A number of institutional investors have recently made changes to their positions in the business. Aberdeen Group plc grew its position in shares of Shattuck Labs by 462.1% during the fourth quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock worth $1,939,000 after buying an additional 436,673 shares in the last quarter. Keel Point LLC acquired a new position in Shattuck Labs during the 3rd quarter worth $110,000. Mallini Complete Financial Planning LLC acquired a new position in Shattuck Labs during the 4th quarter worth $83,000. Bridgeway Capital Management LLC increased its position in shares of Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Shattuck Labs during the third quarter worth about $46,000. 58.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

STTK has been the topic of a number of recent research reports. Piper Sandler initiated coverage on Shattuck Labs in a research note on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. HC Wainwright boosted their price target on Shattuck Labs from $6.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. Wedbush upped their price target on Shattuck Labs from $8.00 to $11.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Finally, Cantor Fitzgerald started coverage on shares of Shattuck Labs in a research note on Monday, April 27th. They set an “overweight” rating on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.